Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Other Non-Current Assets (2016 - 2025)

Cytosorbents (CTSO) has disclosed Other Non-Current Assets for 14 consecutive years, with $3.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets fell 43.75% year-over-year to $3.6 million, compared with a TTM value of $3.6 million through Sep 2025, down 43.75%, and an annual FY2024 reading of $1.5 million, down 62.51% over the prior year.
  • Other Non-Current Assets was $3.6 million for Q3 2025 at Cytosorbents, up from $1.5 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $6.5 million in Q3 2024 and bottomed at $256591.0 in Q4 2021.
  • Average Other Non-Current Assets over 5 years is $3.5 million, with a median of $4.0 million recorded in 2023.
  • Peak annual rise in Other Non-Current Assets hit 1629.39% in 2022, while the deepest fall reached 65.31% in 2022.
  • Year by year, Other Non-Current Assets stood at $256591.0 in 2021, then soared by 1629.39% to $4.4 million in 2022, then decreased by 10.79% to $4.0 million in 2023, then crashed by 62.51% to $1.5 million in 2024, then skyrocketed by 145.75% to $3.6 million in 2025.
  • Business Quant data shows Other Non-Current Assets for CTSO at $3.6 million in Q3 2025, $1.5 million in Q2 2025, and $1.5 million in Q1 2025.